Form 4: Merck Executive Brian Foard Reports Stock Transactions
Statement of Changes in Beneficial Ownership
Merck & Co., Inc. EVP Brian Foard reported transactions involving restricted stock units and stock options on May 5, 2026.
Summary
- Brian Foard, EVP, Specialty, Pharma, & ID at Merck & Co., Inc., reported several transactions on May 5, 2026.
- These transactions include the acquisition of 10,605 Restricted Stock Units (RSUs) and 35,351 RSUs.
- Additionally, 31,044 Stock Options (Right to Buy) were acquired with an exercise price of $113.15.
- The RSUs vest and distribute shares in three equal installments on May 5, 2027, May 5, 2028, and May 5, 2029.
- The stock options also vest and become exercisable in equal installments on May 5, 2027, May 5, 2028, and May 5, 2029.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine executive compensation transactions rather than significant strategic or financial events.
Positives
- Acquisition of significant equity-based compensation (RSUs and stock options) by a key executive, indicating continued incentive and alignment with company performance.
- The vesting schedule for both RSUs and stock options is spread over three years, promoting long-term employee retention and commitment.
Future Outlook
The vesting schedule indicates a multi-year outlook for the realization of these equity awards, aligning executive incentives with the company's long-term performance.
Industry Context
StockSavvy.ai notes that the reporting of equity awards to executives is a standard practice in the pharmaceutical industry, reflecting common compensation structures designed to retain talent and align interests with shareholders.
Stakeholder Impact
- Shareholders: The acquisition of equity by a key executive reinforces alignment of management interests with shareholder value creation.
- Employees: This filing is part of the broader compensation framework for executives, which can influence overall employee morale and retention strategies.
- Management: The grants reflect ongoing compensation and incentive structures for senior leadership.
Next Steps
- Vesting of Restricted Stock Units and Stock Options in installments on May 5, 2027, May 5, 2028, and May 5, 2029.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Earliest transaction date reported for Restricted Stock Units and Stock Options. |
| 05/05/2027 | First vesting date for a portion of the Restricted Stock Units and Stock Options. |
| 05/05/2028 | Second vesting date for a portion of the Restricted Stock Units and Stock Options. |
| 05/05/2029 | Final vesting date for a portion of the Restricted Stock Units and Stock Options. |
| 05/07/2026 | Date the Form 4 was signed by the attorney-in-fact. |
Keywords
Form 4, SEC Filing, Merck & Co., MRK, Brian Foard, Restricted Stock Units, Stock Options, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.